Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden kidney trouble: high blood pressure study in kazakhstan aims to find the missing cases

NCT ID NCT06744335

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 01, 2026 · Updated 5 times

Summary

This study is tracking over 1,200 adults in Kazakhstan who have high blood pressure to see how many also have signs of chronic kidney disease (CKD). Researchers will measure things like protein in urine and kidney function. The goal is to understand how often CKD goes undiagnosed in this group and what treatments patients are actually receiving.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors in Kazakhstan diagnose kidney disease earlier in patients with high blood pressure, leading to better care.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly improve health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,283 people

The number who actually took part.

Started

Jan 2025

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The planned study population for the prospective analysis consists of 1,282 adult outpatients with AH with one or more markers of CKD, without a documented diagnosis of CKD before inclusion in the study and without a documented diagnosis of DM or III-IV stage chronic heart failure (CHF). The planned number of study centers is \~15 outpatient sites in approximately 10 regions of Kazakhstan. The retrospective part includes a physician's retrospective review of the ambulatory cards or medical records of outpatients with a reported diagnosis of arterial hypertension for the presence of laboratory markers of CKD assessed ≥3 and ≤12 months prior to inclusion.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age ≥18 years at the time of inclusion; * Patient signed and dated written informed consent form (ICF) in accordance with ICH GCP and local legislation prior to inclusion in the study for the prospective observational cohort; * Established diagnosis of hypertension, diagnosed in accordance with current clinical guidelines for hypertension, i.e. in adults, i.e. systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg. when measured at two different visits * Laboratory markers of CKD (eGFR \<60 mL/min/1.73 m2 and/or albuminuria/proteinuria\*) measured during the period ≤12 months prior to inclusion in the study and persisting ≥3 months between two measurements without a recorded diagnosis of CKD in the primary medical record prior to inclusion; \* any of the following: urine albumin/creatinine ratio (UACR) ≥30 mg/g (3 mg/mmol), Urine protein-creatinine ratio (uPCR) ≥150 mg/g (15 mg/mmol), albuminuria ≥30 mg/d or Urine protein-creatinine ratio (uPCR) ≥0.15 mg/d. * Absence of documented diagnosis of CKD in the patient's medical records prior to inclusion in the study Exclusion Criteria: * Absence of a signed ICF in patients in the prospective follow-up group * Participation in any randomized controlled trial within 3 months prior to inclusion in this study or during participation in this study * An established diagnosis of type 1 or type 2 diabetes mellitus. * Diagnosis of symptomatic chronic heart failure (CHF), NYHA functional class III-IV, documented in the patient's medical records * Diagnosis of AH of secondary genesis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Demographic and clinical characteristics for those patients Rate of CKD diagnosis in patients with ah and CKD markers Routine therapy before and after the diagnosis of CKD

Contacts and locations

Locations

  • AIS Clinic

    Astana, Kazakhstan

  • City Cardiology Center

    Almaty, Kazakhstan

  • City Polyclinic No. 1

    Karaganda, Kazakhstan

  • City Polyclinic No. 2

    Astana, Kazakhstan

  • City Polyclinic No. 3

    Karaganda, Kazakhstan

  • City Polyclinic No. 4

    Aktobe, Kazakhstan

  • Clinical and Diagnostic Center of the International Kazakh-Turkish University named after Khoja Ahmet Yasawi

    Turkestan, Kazakhstan

  • Communal State Enterprise Polyclinic No. 4 of Kostanay City

    Kostanay, Kazakhstan

  • Communal State Enterprise on the right of economic management City Polyclinic No. 7

    Semey, Kazakhstan

  • Enbekshikazakh Multidisciplinary Interdistrict Hospital

    Esik, Kazakhstan

  • Family Health Center Shipager

    Astana, Kazakhstan

  • Green Clinic

    Astana, Kazakhstan

  • IE Dr.Selina

    Stepnogorsk, Kazakhstan

  • Interna Clinic, Scientific Centre for Internal Medicine LLP

    Almaty, Kazakhstan

  • JSC Research Institute of Cardiology and Internal Diseases

    Almaty, Kazakhstan

  • LLP Almaty Sema Hospital

    Almaty, Kazakhstan

  • LLP Sau Zhurek Healthy Heart

    Shymkent, Kazakhstan

  • Medical Center Hospital of the President's Affairs Administration of the Republic of Kazakhstan

    Astana, Kazakhstan

  • Medical Center Zhanuya

    Astana, Kazakhstan

  • Municipal state enterprise with the right of economic management City polyclinic No. 5

    Almaty, Kazakhstan

  • NJSC Heart Centre Shymkent

    Shymkent, Kazakhstan

  • National Hospital of Medical Center of the Presidents Affairs Administration of the Republic of Kazakhstan

    Almaty, Kazakhstan

  • Onege Family Health and Happiness Centre, LLP

    Astana, Kazakhstan

  • Ordabasy Central District Hospital

    Temirlanovka, Turkistan Oblast, Kazakhstan

  • State Enterprise on the Right of Economic Management City Polyclinic No. 5 Astana

    Astana, Kazakhstan

  • State Enterprise on the Right of Economic Management City Polyclinic No. 6 Astana

    Astana, Kazakhstan

  • State Enterprise on the Right of Economic Management Zhambyl District Central Hospital

    Uzynaghash, Kazakhstan

  • UMC Diagnostic Centre

    Astana, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.